Bladder cancer
Molecular diagnostics in the era of targeted therapies for mUCa
Obiettivo della formazione: Assess the relevance of molecular tumour testing to guide the management of metastatic urothelial carcinoma (mUCa). Recognise molecular biomarkers, sample types and molecular assays to employ molecular tumour testing for mUCa.
Specializzazione: Medical oncology, urology, clinical oncology
Pubblico target: Specialists (CME: intermediate, advanced), Residents (senior)
Aggiornamento più recente: May 2024
Premessa:
Regulatory approval status of drugs and companion diagnostics included in this topic (indications limited to the mUCa setting, status 3 April 2024)
